Dec 18 (Reuters) - Mirum Pharmaceuticals said on Monday its experimental adjuvant therapy to treat a type of liver disease did not meet main goal in mid-stage study. (Reporting by Khushi Mandowara in Bengaluru; Editing by Maju Samuel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.46 USD | -0.12% | +2.73% | -17.14% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.14% | 1.15B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharma's liver disease therapy fails in mid-stage study